In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Molina Healthcare, with a price target of $220.00. The company’s shares closed yesterday at $192.39.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Wilkes is an analyst with an average return of -1.1% and a 47.73% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, HCA Healthcare, and Elevance Health.
In addition to Bernstein, Molina Healthcare also received a Buy from TR | OpenAI – 4o’s Soren Coverra in a report issued on October 14. However, today, TD Cowen downgraded Molina Healthcare (NYSE: MOH) to a Hold.
MOH market cap is currently $10.43B and has a P/E ratio of 9.49.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is neutral on the stock. Most recently, in August 2025, Ronna Romney, a Director at MOH sold 700.00 shares for a total of $107,618.00.
Read More on MOH:
Disclaimer & DisclosureReport an Issue
- Molina Healthcare downgraded to Hold from Buy at TD Cowen
- AMD upgraded, Micron downgraded: Wall Street’s top analyst calls
- Molina Healthcare price target raised to $210 from $180 at Truist
- Molina Healthcare price target raised to $204 from $163 at Morgan Stanley
- Molina Healthcare initiated with a Neutral at Goldman Sachs
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
